CAI
Caris Life Sciences, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 148.22K | +485.1% | $3.60M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | TD Waterhouse Canada Inc. | 300 | 0.0% | $8,517 | 0.0% | Held | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 200 holders, 153.41M shares, $2.53B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 7.50K sh · $238,626
Officer, Director · 400.00K sh · $12.13M
Officer · 119.21K sh · $2.95M
Officer · 393.10K sh · $9.73M
Officer · 84.90K sh · $2.15M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology